D. Witchell

Antisense oligonucleotide therapy for TTR amyloidosis

M. Benson, B. Monia, B. Kluve-Beckerman, 2011, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Antisense Oligonucleotide Blockade of Tumor Necrosis Factor-α in Two Murine Models of Colitis

K. Myers, B. Baker, K. Madsen, 2003, Journal of Pharmacology and Experimental Therapeutics.

Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice.

B. Monia, N. Dean, S. Murray, 2002, Diabetes.

Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice[S]

Richard G. Lee, M. Graham, R. Crooke, 2011, Journal of Lipid Research.

Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild-type mice.

U. Steinbrecher, S. Murray, M. Graham, 2000, The Journal of pharmacology and experimental therapeutics.

Antisense oligonucleotide blockade of alpha 4 integrin prevents and reverses clinical symptoms in murine experimental autoimmune encephalomyelitis

M. Graham, K. Myers, T. Condon, 2005, Journal of Neuroimmunology.

Antisense oligonucleotide blockade of tumor necrosis factor-alpha in two murine models of colitis.

K. Myers, B. Baker, K. Madsen, 2003, The Journal of pharmacology and experimental therapeutics.

Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals.

D. Witchell, A. Siwkowski, T. P. Prakash, 2009, Journal of medicinal chemistry.

Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo.

E. Lesnik, M. Manoharan, B. Monia, 2003, Antisense & nucleic acid drug development.

Antisense Oligonucleotide Blockade of Tumor Necrosis Factor-(cid:1) in Two Murine Models of Colitis

K. Myers, B. Baker, K. Madsen, 2002 .